CO6150193A2 - Terapia tumoral con anticuerpo anti-vegf - Google Patents
Terapia tumoral con anticuerpo anti-vegfInfo
- Publication number
- CO6150193A2 CO6150193A2 CO09018558A CO09018558A CO6150193A2 CO 6150193 A2 CO6150193 A2 CO 6150193A2 CO 09018558 A CO09018558 A CO 09018558A CO 09018558 A CO09018558 A CO 09018558A CO 6150193 A2 CO6150193 A2 CO 6150193A2
- Authority
- CO
- Colombia
- Prior art keywords
- medicament
- antibody
- treatment
- use according
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
1.- El uso de un anticuerpo anti-VEGF para la elaboración de un medicamento para el tratamiento de un paciente que padece una recaída de cáncer HER2 positivo, durante o después del tratamiento con un anticuerpo anti-HER2. 2.- El uso de acuerdo con la reivindicación 1 que se caracteriza porque dicho medicamento se administra al paciente durante el tratamiento con un anticuerpo anti-HER2. 3.- El uso de acuerdo con la reivindicación 2 que se caracteriza porque dicho medicamento se administra durante una monoterapia de primera elección con un anticuerpo anti-HER2. 4.- El uso de acuerdo con la reivindicación 1 que se caracteriza porque dicho medicamento se administra tras el tratamiento con un anticuerpo anti-HER2. 5.- El uso de acuerdo con la reivindicación 4 que se caracteriza porque dicho medicamento se administra tras una monoterapia de primera elección con un anticuerpo antiHER2. 6.- El uso de un anticuerpo anti-VEGF para la elaboración de un medicamento para prevenir o reducir la metástasis en un paciente, que padece una recaída de cáncer HER2 positivo, durante o después del tratamiento con un anticuerpo anti-HER2.7.- El uso de acuerdo con la reivindicación 6 que se caracteriza porque dicho medicamento se administra durante el tratamiento con un anticuerpo anti-HER2. 8.- El uso de acuerdo con la reivindicación 7 que se caracteriza porque dicho medicamento se administra durante una monoterapia de primera elección con un anticuerpo anti-HER2. 9.- El uso de acuerdo con la reivindicación 6 que se caracteriza porque dicho medicamento se administra tras el tratamiento con un anticuerpo anti-HER2. 10.- El uso de acuerdo con la reivindicación 9 que se caracteriza porque dicho medicamento se administra tras una monoterapia de primera elección con un anticuerpo anti-HER2. 11.- El uso de acuerdo con cualquiera de las reivindicaciones 1 a 10, que se caracteriza porque dicho anti-VEGF es bevacizumab. 12.- El uso de cualquiera de las reivindicaciones 1 a 11, que se caracteriza porque dicho anticuerpo anti-HER2 es trastuzumab.13.- Un anticuerpo anti-VEGF para el tratamiento de un paciente que padece una recaída de cáncer HER2 positivo, durante o después del tratamiento con un anticuerpo anti-HER2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06017330 | 2006-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6150193A2 true CO6150193A2 (es) | 2010-04-20 |
Family
ID=37607207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09018558A CO6150193A2 (es) | 2006-08-21 | 2009-02-24 | Terapia tumoral con anticuerpo anti-vegf |
Country Status (29)
Country | Link |
---|---|
US (6) | US20080050385A1 (es) |
EP (2) | EP2441472B1 (es) |
JP (3) | JP2010501498A (es) |
KR (1) | KR101136763B1 (es) |
CN (1) | CN101505792B (es) |
AR (1) | AR062419A1 (es) |
AU (1) | AU2007287794B2 (es) |
BR (1) | BRPI0715829A2 (es) |
CA (1) | CA2660681A1 (es) |
CL (1) | CL2007002404A1 (es) |
CO (1) | CO6150193A2 (es) |
CR (1) | CR10590A (es) |
DK (1) | DK2056874T3 (es) |
ES (2) | ES2546066T3 (es) |
HK (1) | HK1134441A1 (es) |
IL (2) | IL196810A0 (es) |
MA (1) | MA30654B1 (es) |
MX (1) | MX2009001715A (es) |
MY (1) | MY150756A (es) |
NO (1) | NO20090450L (es) |
NZ (1) | NZ574580A (es) |
PE (1) | PE20080911A1 (es) |
PL (1) | PL2056874T3 (es) |
RU (1) | RU2528884C2 (es) |
SG (1) | SG174090A1 (es) |
SI (1) | SI2056874T1 (es) |
TW (2) | TW200825106A (es) |
WO (1) | WO2008022746A1 (es) |
ZA (1) | ZA200901200B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698265A (zh) * | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
KR20160096228A (ko) | 2004-07-22 | 2016-08-12 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ZA200704796B (en) * | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
EP2441472B1 (en) * | 2006-08-21 | 2015-06-10 | F. Hoffmann-La Roche AG | Tumor therapy with an anti-VEGF antibody |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
AU2011257121A1 (en) | 2010-05-27 | 2013-01-10 | Genmab A/S | Monoclonal antibodies against HER2 |
CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
EP2596364B1 (en) * | 2010-07-19 | 2015-12-16 | F.Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
CU24094B1 (es) * | 2010-08-20 | 2015-04-29 | Novartis Ag | Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3) |
CN103796677B (zh) | 2011-04-20 | 2019-08-16 | 健玛保 | 针对her2和cd3的双特异性抗体 |
DK2766040T3 (da) | 2011-10-14 | 2019-07-22 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie |
JP2015502543A (ja) * | 2011-12-05 | 2015-01-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 乳癌治療向けベバシズマブ併用療法用血漿バイオマーカー |
US20150147340A1 (en) * | 2012-03-30 | 2015-05-28 | Fibrogen, Inc. | Therapeutic methods for peritoneal carcinomatosis |
AR095863A1 (es) | 2013-04-16 | 2015-11-18 | Genentech Inc | Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación |
EP3134440A1 (en) | 2014-04-25 | 2017-03-01 | F. Hoffmann-La Roche AG | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
EP3302551A2 (en) | 2015-05-30 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
TWI734775B (zh) * | 2016-04-26 | 2021-08-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
RU2750821C2 (ru) | 2017-01-17 | 2021-07-05 | Дженентек, Инк. | Препараты антител против her2 для подкожного введения |
FI3589661T3 (fi) | 2017-03-02 | 2024-01-31 | Genentech Inc | Her2-positiivisen rintasyövän adjuvanttihoito |
CN110536969A (zh) | 2017-04-24 | 2019-12-03 | 豪夫迈·罗氏有限公司 | 跨膜或近膜域中的erbb2/her2突变 |
US20230330094A1 (en) * | 2020-09-04 | 2023-10-19 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Combination compositions and methods for treating cancer |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
JPH11512750A (ja) | 1996-06-27 | 1999-11-02 | ファイザー インク. | 2―(2―オキソ―エチリデン)―イミダゾリジン―4―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法 |
NZ519191A (en) | 1996-10-18 | 2005-04-29 | Univ Texas | Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies |
EP3260468A1 (en) | 1997-04-07 | 2017-12-27 | Genentech, Inc. | Anti-vegf antibodies |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−4−オン誘導体 |
MXPA00011248A (es) | 1998-05-15 | 2004-09-06 | Imclone Systems Inc | Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento. |
WO2000012498A1 (en) | 1998-08-27 | 2000-03-09 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
JP3495706B2 (ja) | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体 |
DK1135498T3 (da) | 1998-11-18 | 2008-05-26 | Genentech Inc | Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer |
EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
AU1687500A (en) | 1998-12-16 | 2000-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Antihuman vegf monoclonal antibody |
EA200100766A1 (ru) | 1999-02-11 | 2002-02-28 | Пфайзер Продактс Инк. | Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов |
US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
ES2320311T3 (es) | 1999-05-14 | 2009-05-21 | Genentech, Inc. | Tratamiento con anticuerpos anti-erbb2. |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
JP4579471B2 (ja) | 1999-06-25 | 2010-11-10 | ジェネンテック, インコーポレイテッド | 抗ErbB2抗体を用いる前立腺癌の処置 |
EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
PT1106612E (pt) | 1999-11-30 | 2004-06-30 | Pfizer Prod Inc | Derivados de quinolina uteis para inibir a farnesil-proteina-transferase |
HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
WO2003042402A2 (en) * | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
AU2003222252A1 (en) | 2002-03-12 | 2003-09-29 | The General Hospital Corporation | Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
CA2481515C (en) | 2002-04-10 | 2013-10-01 | Genentech, Inc. | Anti-her2 antibody variants |
US20040243207A1 (en) | 2003-05-30 | 2004-12-02 | Olson Donald R. | Medical implant systems |
MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
KR20060069825A (ko) | 2003-08-01 | 2006-06-22 | 제넨테크, 인크. | 제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열 |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
CA2577082A1 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
ZA200701789B (en) * | 2004-10-04 | 2008-11-26 | Genentech Inc | Modulators of hepatocyte growth factor activator |
RU2596491C2 (ru) * | 2005-06-08 | 2016-09-10 | Дана-Фарбер Кэнсер Инститьют | Способы и композиции для лечения персистирующих инфекций |
TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
EP2441472B1 (en) * | 2006-08-21 | 2015-06-10 | F. Hoffmann-La Roche AG | Tumor therapy with an anti-VEGF antibody |
JP2013103182A (ja) * | 2011-11-15 | 2013-05-30 | Toray Ind Inc | スパイラル型流体分離素子およびその製造方法 |
-
2007
- 2007-08-17 EP EP11193793.4A patent/EP2441472B1/en not_active Revoked
- 2007-08-17 RU RU2009110102/15A patent/RU2528884C2/ru not_active IP Right Cessation
- 2007-08-17 ES ES11193793.4T patent/ES2546066T3/es active Active
- 2007-08-17 WO PCT/EP2007/007276 patent/WO2008022746A1/en active Application Filing
- 2007-08-17 SI SI200731075T patent/SI2056874T1/sl unknown
- 2007-08-17 CN CN2007800308557A patent/CN101505792B/zh not_active Expired - Fee Related
- 2007-08-17 US US11/840,279 patent/US20080050385A1/en not_active Abandoned
- 2007-08-17 DK DK07786693.7T patent/DK2056874T3/da active
- 2007-08-17 CL CL200702404A patent/CL2007002404A1/es unknown
- 2007-08-17 MY MYPI20090667 patent/MY150756A/en unknown
- 2007-08-17 AR ARP070103667A patent/AR062419A1/es unknown
- 2007-08-17 BR BRPI0715829-7A2A patent/BRPI0715829A2/pt not_active Application Discontinuation
- 2007-08-17 EP EP07786693A patent/EP2056874B1/en not_active Revoked
- 2007-08-17 JP JP2009524943A patent/JP2010501498A/ja active Pending
- 2007-08-17 KR KR1020097003557A patent/KR101136763B1/ko not_active IP Right Cessation
- 2007-08-17 CA CA002660681A patent/CA2660681A1/en not_active Abandoned
- 2007-08-17 MX MX2009001715A patent/MX2009001715A/es active IP Right Grant
- 2007-08-17 SG SG2011060142A patent/SG174090A1/en unknown
- 2007-08-17 NZ NZ574580A patent/NZ574580A/en not_active IP Right Cessation
- 2007-08-17 PL PL07786693T patent/PL2056874T3/pl unknown
- 2007-08-17 ES ES07786693T patent/ES2392630T3/es active Active
- 2007-08-17 AU AU2007287794A patent/AU2007287794B2/en not_active Ceased
- 2007-08-20 TW TW096130765A patent/TW200825106A/zh unknown
- 2007-08-20 PE PE2007001129A patent/PE20080911A1/es not_active Application Discontinuation
- 2007-08-20 TW TW099141756A patent/TW201107346A/zh unknown
-
2009
- 2009-01-29 NO NO20090450A patent/NO20090450L/no not_active Application Discontinuation
- 2009-01-29 CR CR10590A patent/CR10590A/es not_active Application Discontinuation
- 2009-01-29 IL IL196810A patent/IL196810A0/en unknown
- 2009-02-19 MA MA31650A patent/MA30654B1/fr unknown
- 2009-02-19 ZA ZA2009/01200A patent/ZA200901200B/en unknown
- 2009-02-24 CO CO09018558A patent/CO6150193A2/es unknown
-
2010
- 2010-02-10 HK HK10101487.6A patent/HK1134441A1/xx not_active IP Right Cessation
- 2010-05-20 US US12/784,309 patent/US20100285010A1/en not_active Abandoned
-
2011
- 2011-05-19 US US13/111,784 patent/US20110223159A1/en not_active Abandoned
-
2012
- 2012-08-14 US US13/585,095 patent/US20130183292A1/en not_active Abandoned
-
2013
- 2013-05-15 JP JP2013103182A patent/JP2013163687A/ja not_active Withdrawn
-
2015
- 2015-03-30 IL IL238045A patent/IL238045A0/en unknown
- 2015-05-13 US US14/711,671 patent/US20150239969A1/en not_active Abandoned
- 2015-08-14 JP JP2015160099A patent/JP2015214582A/ja not_active Ceased
-
2017
- 2017-10-23 US US15/791,285 patent/US20180251536A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6150193A2 (es) | Terapia tumoral con anticuerpo anti-vegf | |
AR109246A2 (es) | USO DE UN INMUNOCONJUGADO QUE COMPRENDE UN ANTICUERPO ANTI-ErbB2 PARA LA MANUFACTURA DE UN MEDICAMENTO | |
CR10244A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
DOP2017000177A (es) | Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer | |
EA201170592A1 (ru) | Комбинированная терапия с применением пептид эпоксикетонов | |
PE20080663A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti-her2 | |
DOP2012000291A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer de mama | |
HK1243943A1 (zh) | 使用抗IL-1α抗體治療癌症 | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CL2012000229A1 (es) | Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular. | |
CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
MX2010003815A (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. | |
AR075982A1 (es) | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion | |
RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
AR050036A1 (es) | Anticuerpos anti - igf- ir y sus usos | |
EA200970317A1 (ru) | Комбинированное лечение опухолей, экспрессирующих cd38 | |
AR074203A1 (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso. | |
PA8635501A1 (es) | Uso de un anticuerpo para el tratamiento del lupus | |
AR076344A1 (es) | Metodo de terapia complementaria contra el cancer | |
ATE534386T1 (de) | Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper | |
MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy |